Showing results for "Epigenomics"
businessweek
Big Pharma Bets on a Novel Cancer CureDrug companies have long hawked cancer treatments that either kill tumors outright with chemotherapy or use pricey medicines to block the mutated genes that fuel cancer's growth. Recently, drugmakers including GlaxoSmithKline (GSK), Eli Lilly (LLY), and Novartis (NVS) have begun chasing a third approach: reprogramming the aberrant DNA that can turn cells cancerous in the first place.May 12, 2011
business
Cancer Sleuths Uncovering DNA Mysteries for Novartis, GlaxoMost existing cancer treatments either kill tumors outright with toxic chemotherapy or block mutated genes that fuel tumor growth. Now drugmakers including GlaxoSmithKline Plc, Eli Lilly & Co., and Novartis AG are chasing a third approach: reprogramming aberrant DNA that can turn cells cancerous in the first place.May 12, 2011